NCT03517631 is a Phase 1 clinical trial of shRNA-modified CD34+ cells in HIV Infections, sponsored by Shanghai Public Health Clinical Center.

Who is sponsoring NCT03517631?

NCT03517631 is sponsored by Shanghai Public Health Clinical Center.

What drugs are being tested in NCT03517631?

Interventions in NCT03517631: shRNA-modified CD34+ cells, Low dose busulfan preconditioning, Busulfan preconditioning.

What condition does NCT03517631 study?

NCT03517631 studies HIV Infections, AIDS.

Is NCT03517631 still recruiting?

NCT03517631 is currently status unknown. Last updated 19 February 2020.

Last reviewed 2020-02-19 · How we verify

NCT03517631

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients.

Status unknown Phase 1 Last updated 19 February 2020

What this trial tests

Phase 1 trial testing shRNA-modified CD34+ cells in HIV Infections in 6 participants. Status unknown.

Timeline

27 February 2018

Primary endpoint
15 December 2020

31 December 2020

Quick facts

Lead sponsor	Shanghai Public Health Clinical Center
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	27 February 2018
Primary completion	15 December 2020
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

shRNA-modified CD34+ cells — full drug profile →
Low dose busulfan preconditioning — full drug profile →
Busulfan preconditioning — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →
AIDS — all drugs for AIDS →

Sponsor

Shanghai Public Health Clinical Center

Who can join

Adults 18 to 50, any sex, with HIV Infections or AIDS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the efficacy and safety of autologous CD34+ cells that stably express multiplexed shRNA to treat HIV infection.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

RNA Interference as a Prospective Tool for the Control of Human Viral Infections.
Levanova A, Poranen MM. · · 2018 · cited 73× · PMID 30254624 · DOI 10.3389/fmicb.2018.02151
Block-And-Lock: New Horizons for a Cure for HIV-1.
Moranguinho I, Valente ST. · · 2020 · cited 69× · PMID 33334019 · DOI 10.3390/v12121443
Deep Thought on the HIV Cured Cases: Where Have We Been and What Lies Ahead?
Xiao Q, He S, Wang C, Zhou Y, et al · · 2025 · cited 3× · PMID 40149913 · DOI 10.3390/biom15030378

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other Shanghai Public Health Clinical Center trials

Trials by the same sponsor.

NCT07526363 — Real-world Cohort Study of Antiretroviral Therapy in HIV Patients With Opportunistic Infections · not yet recruiting
NCT06940375 — Incidence of Liver Disease-Related Outcomes in People With HIV · recruiting
NCT06926569 — Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis · NA · not yet recruiting
NCT06768697 — Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant · EARLY_PHASE1 · not yet recruiting
NCT05129189 — Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03517631 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Public Health Clinical Center
Last refreshed: 19 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03517631.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing